Literature DB >> 8226281

Triflavin, an Arg-Gly-Asp-containing peptide, inhibits tumor cell-induced platelet aggregation.

J R Sheu1, C H Lin, H C Peng, C M Teng, T F Huang.   

Abstract

In this study, we examined the effect of triflavin, an Arg-Gly-Asp (RGD)-containing snake venom peptide, on human cervical carcinoma (HeLa) cell- and B16-F10 mouse melanoma cell-induced platelet aggregation (TCIPA) in heparinized platelet-rich plasma. TCIPA appears to play an important role in the development of certain experimental tumor metastases. Two ADP-scavenging agents, apyrase (10 U/ml) and creatine phosphate (CP) (5 mM)/creatine phosphokinase (CPK) (5 U/ml) completely inhibited B16-F10 TCIPA, but hirudin (5 U/ml) had no effect. In contrast, apyrase and CP/CPK did not inhibit HeLa TCIPA while hirudin completely inhibited it. Furthermore, HeLa cells initially induced platelet aggregation and then blood coagulation at a later stage. In addition, HeLa cells shortened, in a concentration-dependent manner, the recalcification time of normal as well as factor VIII- and IX-deficient human plasma, but did not affect the recalcification time of factor VII-deficient plasma. This suggests that HeLa TCIPA occurs via activation of the extrinsic pathway, probably owing to tumor cell expression of tissue factor-like activity. HeLa cell-induced thrombin generation was confirmed by detection of amidolytic activity towards a chromogenic substrate, S-2238 (H-D-Phe-Pip-Arg-p-NA). Triflavin and GRGDS inhibited, in a dose-dependent manner, TCIPA caused by either cell line. On a molar basis, triflavin was 10,000-30,000 times more potent than GRGDS in this regard. Moreover, monoclonal antibodies raised against glycoprotein (GP) IIb/IIIa complex (i.e., 7E3 and AP2) and against GP Ib (i.e., AP1) completely inhibited HeLa TCIPA. 7E3 and AP2 inhibited B16-F10 TCIPA by up to 80% whereas AP1 showed only 30% inhibition of B16-F10 TCIPA. In conclusion, the inhibitory effect of triflavin on HeLa and B16-F10 TCIPA may be mediated principally by the binding of triflavin to the fibrinogen receptor associated with GP IIb/IIIa complex on the platelet surface. However, GP Ib is also involved in HeLa TCIPA as thrombin formation is the key factor in triggering platelet aggregation caused by HeLa cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8226281      PMCID: PMC5919057          DOI: 10.1111/j.1349-7006.1993.tb02802.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


tumor cell‐induced platelet aggregation Dulbecco's modified Eagle's medium Giy‐ArgGlyAspSer GlyArgGlyGluSer fetal calf serum glycoprotein platelet‐rich plasma platelet‐poor plasma phosphate‐buffered saline creatine phosphate creatine phosphokinase Ca2+, Mg2+‐free Hanks’ balanced salt solution
  47 in total

1.  Tumor-cell-induced platelet aggregation is a glycoprotein-dependent and lipoxygenase-associated process.

Authors:  E Bastida; L Almirall; A Ordinas
Journal:  Int J Cancer       Date:  1987-06-15       Impact factor: 7.396

2.  Involvement of platelet membrane glycoprotein Ib and glycoprotein IIb/IIIa complex in thrombin-dependent and -independent platelet aggregations induced by tumor cells.

Authors:  H Kitagawa; N Yamamoto; K Yamamoto; K Tanoue; G Kosaki; H Yamazaki
Journal:  Cancer Res       Date:  1989-02-01       Impact factor: 12.701

3.  Halysin, an antiplatelet Arg-Gly-Asp-containing snake venom peptide, as fibrinogen receptor antagonist.

Authors:  T F Huang; C Z Liu; C H Ouyang; C M Teng
Journal:  Biochem Pharmacol       Date:  1991-08-22       Impact factor: 5.858

4.  Triflavin, an antiplatelet Arg-Gly-Asp-containing peptide, is a specific antagonist of platelet membrane glycoprotein IIb-IIIa complex.

Authors:  T F Huang; J R Sheu; C M Teng; S W Chen; C S Liu
Journal:  J Biochem       Date:  1991-02       Impact factor: 3.387

5.  Tumor cell-platelet interactions in vitro and their relationship to in vivo arrest of hematogenously circulating tumor cells.

Authors:  D G Menter; J S Hatfield; C Harkins; B F Sloane; J D Taylor; J D Crissman; K V Honn
Journal:  Clin Exp Metastasis       Date:  1987 Jan-Mar       Impact factor: 5.150

6.  The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets.

Authors:  T K Gartner; J S Bennett
Journal:  J Biol Chem       Date:  1985-10-05       Impact factor: 5.157

7.  Effects of 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride (Ticlopidine), a platelet aggregation inhibitor, on blood-borne metastasis.

Authors:  S Kohga; M Kinjo; K Tanaka; H Ogawa; M Ishihara; N Tanaka
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

8.  Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor, dansylarginine N-(3-ethyl-1,5-pentanediyl)amide.

Authors:  E Pearlstein; C Ambrogio; G Gasic; S Karpatkin
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

9.  Platelet-cancer cell interaction in metastasis formation: a possible therapeutic approcach to metastasis prophylaxis.

Authors:  H Gastpar
Journal:  J Med       Date:  1977

10.  Lodgement and extravasation of tumour cells in blood-borne metastasis: an electron microscope study.

Authors:  M Kinjo
Journal:  Br J Cancer       Date:  1978-08       Impact factor: 7.640

View more
  2 in total

Review 1.  Platelet Integrins in Tumor Metastasis: Do They Represent a Therapeutic Target?

Authors:  Marion Lavergne; Emily Janus-Bell; Mathieu Schaff; Christian Gachet; Pierre H Mangin
Journal:  Cancers (Basel)       Date:  2017-09-28       Impact factor: 6.639

2.  Antiplatelet agents for cancer treatment: a real perspective or just an echo from the past?

Authors:  Marek Z Wojtukiewicz; Dominika Hempel; Ewa Sierko; Stephanie C Tucker; Kenneth V Honn
Journal:  Cancer Metastasis Rev       Date:  2017-06       Impact factor: 9.264

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.